Diabetes News and Research

Latest Diabetes News and Research

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.

30 Jun 2011

Early metformin treatment may prevent adolescent polycystic ovary syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that early, prolonged treatment with the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome (PCOS) in adolescence.

30 Jun 2011

Vaccines may be given in food in the near future

Soon children could be vaccinated with bacteria mixed in milk and people in the developing world given unprecedented access to immunisations under a scheme proposed by an Australian Nobel laureate, Barry Marshall.

29 Jun 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that they acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products are approved and some are pending approval with the Food and Drug Administration (FDA).

29 Jun 2011

Diet sodas and artificial sweeteners may not be healthy alternatives

In the constant battle to lose inches or at least stay the same, we reach for the diet soda. Two studies presented June 25 and 27 at the American Diabetes Association's Scientific Sessions in San Diego suggest this might be self-defeating behavior.

29 Jun 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Prototype small molecule drugs could suppress hepatitis C

Targeted multi-drug treatments for hepatitis C patients that could stop the virus in its tracks have come a step closer, thanks to researchers at the University of Leeds, UK.

29 Jun 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

GABA corrects both known causes of Type 1 diabetes

A chemical produced by the same cells that make insulin in the pancreas prevented and even reversed Type 1 diabetes in mice, researchers at St. Michael's Hospital have found.

29 Jun 2011

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera® (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD). Pancreatitis, or inflammation of the pancreas, is a major clinical symptom of LPLD.

29 Jun 2011

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

454 Life Sciences launches new GS FLX+ System for high-throughput sequencing

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long sequencing reads up to 1,000 by in length.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Nine-year-old recovers with experimental heart pump

Nine-year-old Greer Underwood was healthy until February 2011. What seemingly began as sinusitis on a Tuesday became almost fatal by the weekend when her heart began to fail. Now, after a historic series of events at the University of Alabama at Birmingham, she's the only child in the country to have used the experimental heart pump, Heartware, as a bridge to transplant.

28 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

Number of adults with diabetes doubled over past three decades, study shows

The number of adults with type 2 diabetes has doubled worldwide over the last three decades, rising from 153 million in 1980 to 347 million, "a sign that the epidemic will impose an ever-greater cost burden on health systems," according to a study published on Saturday in the Lancet, the Wall Street Journal reports.

28 Jun 2011

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

Diabetes News and Research

Latest Diabetes News and Research

STSI joins JAX consortium to develop targeted cancer therapies

Early metformin treatment may prevent adolescent polycystic ovary syndrome

Vaccines may be given in food in the near future

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Diet sodas and artificial sweeteners may not be healthy alternatives

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

Prototype small molecule drugs could suppress hepatitis C

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

GABA corrects both known causes of Type 1 diabetes

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

454 Life Sciences launches new GS FLX+ System for high-throughput sequencing

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Nine-year-old recovers with experimental heart pump

EAS, ESC develop new European guidelines to manage dyslipidaemias

Number of adults with diabetes doubled over past three decades, study shows

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in